Form ARS Janux Therapeutics, Inc. For: Dec 31
Tweet
Share
E-mailATTACHMENTS / EXHIBITS
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Janux Therapeutics (JANX) PT Lowered to $26 at Truist Securities
- [Ad hoc announcement pursuant to Art. 53 LR] Roche’s divarasib shows superiority in head-to-head phase III trial against approved KRAS G12C inhibitors in non-small cell lung cancer
- Novartis receives European Commission approval for Itvisma® for spinal muscular atrophy (SMA)
Create E-mail Alert Related Categories
SEC FilingsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
